Much controversy surrounds the use of high-sensitivity C-reactive protein (hs-CRP) as a
marker of cardiovascular (CV) risk. Although data regarding the association of hs-CRP with …

Statins for primary prevention of venous thromboembolism - Li, L - 2014 | Cochrane Library Skip
to Content Cookies Our site uses cookies to improve your experience. You can find out more …

Purpose To examine HMG-CoA reductase inhibitor (statin) drug dispensing patterns to Nova
Scotia Seniors' Pharmacare program (NSSPP) beneficiaries over a 14-year period in …

Introduction: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor is a new
treatment option for patients with hypercholesterolemia. The objective of this study was to …

There is increasing interest in utilizing novel markers of cardiovascular disease risk and
consequently, there is a need to assess the value of their use. In this paper, we will review …

Background Real-world patients' medication adherence is lower than that of clinical trial
patients. Hence, the effectiveness of medications in routine practice may differ. Objectives …

Гиперхолестеринемия является самым важным фактором риска развития и
прогрессирования атеросклероза практически во всех популяциях, включая Российскую …

Objective: The availability of hard clinical end-point data, such as that on cardiovascular
(CV) events among patients with type 2 diabetes mellitus, is increasing, and as a result there …

Background: Given the results of the Justification for the Use of Statins in Primary
Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial, statin initiation …

Perhaps no recent trial in primary prevention of cardiovascular disease has resulted in more
controversy than the JUPITER (Justification for the Use of Statins in Prevention: An …